Key result
Iron deprivation using chelators like ICRF-187 prevents anthracycline-induced free radical formation and clinical cardiac toxicity, particularly in the setting of iron overload.
Why the study?
Do iron chelators like ICRF-187 prevent anthracycline-induced cardiotoxicity in patients and preclinical models?
Population
Patients receiving long-term anthracycline therapy and rat heart cell cultures
Design
Review
Authors
Loading...
May support chelation in iron-overloaded anthracycline recipients; leaves open confirmation in prospective trials.
Do iron chelators like ICRF-187 prevent anthracycline-induced cardiotoxicity in patients and preclinical models?
Iron chelation with agents like ICRF-187 may prevent anthracycline-induced cardiotoxicity, which is particularly relevant for patients with iron overload from transfusions.
Hershko et al. (1993) conducted a review in Anthracycline Cardiotoxicity. Iron chelators (e.g., ICRF-187) was evaluated. Iron deprivation using chelators like ICRF-187 prevents anthracycline-induced free radical formation and clinical cardiac toxicity, particularly in the setting of iron overload.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: